LYRA: Lyra Therapeutics, Inc. Book Value per Share

Symbol and logo of brand Lyra Therapeutics, Inc. (LYRA)

Investing in Lyra Therapeutics, Inc. (LYRA) entails risks associated with potential failures in final testing and a dependence on a single technology. The trend in book value per share reflects the dynamics of net assets, with the indicator currently fixed at -2.63. Growth potential is driven by an open niche for non-surgical rhinosinusitis treatment, while the company's reputation as an innovator in precision drug delivery ensures physician loyalty.

LYRA Lyra Therapeutics Inc. Share Book Value (07/04/2022 - 03/28/2026)

Summary analytical data breakdowns for lyratherapeutics.com (LYRA)

- current quotes and average value forecast:
Price Chart Lyra Therapeutics, Inc|LYRA - Fair Value Consensus
- market capitalization information:
Market Capitalization Lyra Therapeutics, Inc.|LYRA - Enterprise Value
- business book valuation details:
Net Assets per Single Share Lyra Therapeutics|LYRA - Net Asset Value|Market Capitalization to Book Value Ratio lyratherapeutics.com|LYRA - Aggregate Asset Value
- debt level and financial liquidity data:
Total Debt to Capital Lyra Therapeutics, Inc.|LYRA - Long-Term Debt to Capital|Short-Term Debt to Equity Lyra Therapeutics|LYRA - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Lyra Therapeutics, Inc.|LYRA - Company Long-Term Liabilities|Company Short-Term Debts Lyra Therapeutics|Quick Liquidity Indicator lyratherapeutics.com
- earnings and multiples data:
LYRA - Final Profit
General company analysis:LYRA - Lyra Therapeutics, Inc
Manufactured products of Lyra Therapeutics

Amidst a critical reduction in resources for Lyra Therapeutics, Inc. (LYRA) due to clinical trial failures, the management of residual capital has become the determining factor for business survival. The trend in net assets per share reflects the difference between all company assets and liabilities, allowing investors to assess the real value of their ownership stake and the degree of capital protection against total devaluation during restructuring.

Competitor analysis

HLN - Net Assets per Single Share|Accounting Value of a Share KVUE (Kenvue Health)|VRNA: Book Value per Share|jyongbio.com (MENS) - Book Value per Share|Net Assets per Single Share Ligand|Amneal Pharmaceuticals, Inc. - Share Book Value|Book Value per Share PRGO|ALVO (Alvotech Biopharmaceuticals) - Accounting Value of a Share|Book Value per Share LQDA (Liquidia Corporation)|Book Value per Share glpg.com GLPG|ANIP - Net Assets per Single Share|Accounting Value of a Share MNKD (MannKind Corp)|Amphastar (AMPH) - Net Assets per Single Share|Accounting Value per Share Pacira Corp|SPRY (ARS Pharmaceuticals) - Book Value per Share|Book Value per Share theravance.com|Accounting Value per Share AQST (Aquestive Therapeutics, Inc.)|SCPH (scpharmaceuticals.com) - Accounting Value of a Share|Net Assets per Single Share Tectonic Therapeutic TECX|Tonix Pharmaceuticals Holding (TNXP) - Net Asset Value per Share|SXTC: Accounting Value per Share|Eupraxia Pharmaceuticals - Book Price of a Share|BHST: Book Value per Share|Invizyne Technologies - Accounting Value of a Share|ORMP (Oramed) - Book Value per Share|Net Asset Value per Share Entera Bio Corp ENTX|Net Assets per Single Share MindWalk Holdings (HYFT)|ABVC (abvcpharma.com) - Accounting Value of a Share|Net Assets per Single Share Cumberland Pharmaceuticals Inc. CPIX|Quantum BioPharma Ltd. - Net Assets per Single Share|FGEN: Accounting Value per Share|Net Asset Value per Share Telomir Pharmaceuticals Corp|ranitherapeutics.com (RANI) - Net Assets per Single Share|Synergy CHC - Accounting Value of a Share|RLYB (Rallybio Corp) - Book Value per Share|Book Value per Share Lexaria|Accounting Value per Share PULM (Pulmatrix Corp)|PTHL (ftzy.com.cn) - Accounting Value of a Share|Aptorum Group - Accounting Value per Share|Book Price of a Share IBO (Impact BioMedical, Inc.)|TNF Pharma - Book Value per Share|Accounting Value of a Share YCBD (cbdMD, Inc.)|PRFX: Book Value per Share|Net Asset Value per Share Altamira Therapeutics Ltd. (CYTO)|Net Assets per Single Share Lipella Pharmaceuticals|OPTN: Accounting Value of a Share|Book Value per Share PIRS|Book Value per Share Procaps Group (PROC)|Net Assets per Single Share Petros PTPI|QLI (Qilian International Corp) - Share Book Value|Acelyrin, Inc. - Book Value per Share|Net Asset Value per Share tffpharma.com